Celgene Co. (NASDAQ:CELG) Shares Sold by O Dell Group LLC

Celgene logo O Dell Group LLC cut its position in Celgene Co. (NASDAQ:CELG) by 5.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 11,546 shares of the biopharmaceutical company’s stock after selling 702 shares during the period. Celgene makes up about 0.5% of O Dell Group LLC’s investment portfolio, making the stock its 23rd largest holding. O Dell Group LLC’s holdings in Celgene were worth $740,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Edgewood Management LLC lifted its holdings in Celgene by 13.2% during the third quarter. Edgewood Management LLC now owns 15,757,525 shares of the biopharmaceutical company’s stock valued at $1,410,141,000 after purchasing an additional 1,832,981 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Celgene by 15.3% during the third quarter. Janus Henderson Group PLC now owns 10,461,658 shares of the biopharmaceutical company’s stock valued at $936,215,000 after purchasing an additional 1,391,617 shares in the last quarter. FMR LLC lifted its holdings in Celgene by 26.0% during the third quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock valued at $919,890,000 after purchasing an additional 2,119,257 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Celgene by 50.2% in the third quarter. Jennison Associates LLC now owns 8,228,124 shares of the biopharmaceutical company’s stock worth $736,335,000 after buying an additional 2,748,302 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in shares of Celgene by 9.2% in the third quarter. Clearbridge Investments LLC now owns 7,133,588 shares of the biopharmaceutical company’s stock worth $638,385,000 after buying an additional 598,631 shares in the last quarter. 72.71% of the stock is owned by institutional investors and hedge funds.

CELG has been the topic of several research analyst reports. Morgan Stanley lowered their target price on shares of Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 19th. Leerink Swann set a $112.00 target price on shares of Celgene and gave the stock a “hold” rating in a report on Friday, October 26th. BidaskClub raised shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. Zacks Investment Research raised shares of Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 target price on the stock in a report on Wednesday, January 23rd. Finally, ValuEngine raised shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene currently has a consensus rating of “Buy” and a consensus target price of $109.29.

Shares of Celgene stock opened at $88.14 on Wednesday. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 4.06. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $97.43. The stock has a market cap of $61.42 billion, a price-to-earnings ratio of 11.58, a price-to-earnings-growth ratio of 0.47 and a beta of 1.72.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.07. The company had revenue of $4.04 billion for the quarter, compared to analysts’ expectations of $3.98 billion. Celgene had a net margin of 26.48% and a return on equity of 125.35%. During the same period in the prior year, the business earned $2.00 EPS. As a group, equities research analysts forecast that Celgene Co. will post 9.39 earnings per share for the current fiscal year.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. Institutional Ownership by Quarter for Celgene (NASDAQ:CELG) Receive News & Ratings for Celgene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celgene and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *